Archived article
Please note that tax, investment, pension and ISA rules can change and the information and any views contained in this article may now be inaccurate.
Vela Technologies PLC on Thursday announced it entered into a put option deal for the right to sell its commercial interest in AZD1656, a Covid application.
The company said it could sell it for £4.0 million. The option is being granted by Conduit Pharmaceuticals Ltd, a clinical stage speciality biopharmaceutical company focused on unmet medical needs in the areas of autoimmune disease and idiopathic male infertility.
Vela shares shot up 49% to 0.024 pence each in London following the announcement on Thursday afternoon.
Vela Executive Director James Normand said: ‘Vela is pleased to have gained, through this transaction with Conduit Pharmaceuticals, the potential to convert an illiquid asset into shares in a publicly listed vehicle. Should the merger between Conduit and Murphy conclude and the option be exercised, Vela will then be in a position to monetise its investment in St George Street Capital, following which it would intend to redeploy such cash proceeds in accordance with its investing policy.’
Vela Technologies is a Bingley, England-based investing company focused on early stage and pre-IPO long term disruptive technology investments.
Copyright 2023 Alliance News Ltd. All Rights Reserved.